Clinical Trial Search

Primary: Change From Baseline in Self-Reported Symptom Scores From Well-to-Sick State Through Day 56 — 0.065; 0.281; 0.036; 0.113 Scores on a scale — p=<.0001

Primary: Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED — 20; 33 Participants

Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year

Primary: Health Related Quality of Life Score — 91.5; 90.2 scores on a scale — p=0.008

Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants

Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants

Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen

Primary: Incidence Rates of First Episode of Respiratory Syncytial Virus (RSV) Respiratory Tract Infection (RTI) [Period 1] — 7.93 Cases per 100 person-years

Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change

Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634

Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020

Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale

Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants

Primary: Number of Participants With at Least One LRTI During Follow-up Period — 16; 20; 17; 138 Participants — p=0.68

Primary: Occurrences of Pneumonia — 4; 3 Participants

Primary: Antibiotic Prescribing Rate at Index Consultation (Immediate or Delayed) — 466; 817 Participants

Primary: Inappropriate Antibiotic Prescribing Rate for Qualifying Acute Respiratory Infection Diagnoses — 0.20; 0.19; 0.08; 0.09 proportion of visits

Primary: Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study — 275; 133 participants

Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049

Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms — 4.1; 5.0 days — p=0.0155

Primary: Total Symptoms Score (TSS) — 0.503; 0.843 scores

Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04

Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days

Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml

Primary: Number of Participants With a Clinical Outcome of "Cure" at Test of Cure (TOC: Day 15) — 23; 3; 0 Participants

Primary: Detection of Respiratory Viruses — 83 participants

Primary: Progression to Clinically Significant Lower Respiratory Tract Symptoms — 35; 57 participants — p=0.04

Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale

Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants

Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms. — 4.1; 4.5 days — p=0.032